First Wave BioPharma Inc

:AZRX   3:57:07 PM EDT
-0.01 (-0.29%)
Products, Regulatory, Earnings Announcements

AzurRx Says Positive Results from DMC Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide

Published: 09/09/2021 13:44 GMT
AzurRx BioPharma Inc (AZRX) - Azurrx Biopharma Announces Positive Results From Independent Data Monitoring Committee Review of Safety Data From Part 1 of Reservoir Phase 2 Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections.
Azurrx Biopharma Inc - Review of Interim Safety Data Concluded With Favorable Recommendation to Continue Reservoir Trial As Planned.
Azurrx Biopharma Inc - Part 2 of Reservoir Trial to Enroll Up to 150 Patients to Evaluate Efficacy of Fw-1022 and Extend Safety Observations.